Runnymede Capital Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Runnymede Capital Advisors’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-150	Closed	-$74.6K	–	248
2025 Q1	$74.6K	Hold	150	–	–	0.07%	100
2024 Q4	$78K	Buy	+150	New	+$82.5K	0.07%	103

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Runnymede Capital Advisors's TMO Position: Q2 2025 in Review

Runnymede Capital Advisors sold out of Thermo Fisher Scientific (TMO) in Q2 2025, closing a stake of 150 shares — an estimated $74.6K sold.

Runnymede Capital Advisors first reported a position in TMO in Q4 2024 and held it in 2 quarters. The position peaked at $78K in Q4 2024. 2,454 funds tracked by Wall St. Rank hold TMO as of Q2 2025.

Runnymede Capital Advisors reported no remaining Thermo Fisher Scientific position as of Q2 2025 after selling out during the quarter.
Runnymede Capital Advisors sold 150 Thermo Fisher Scientific shares in Q2 2025, an estimated $74.6K.
Runnymede Capital Advisors first reported a position in Thermo Fisher Scientific in Q4 2024 and held it in 2 quarters.
Runnymede Capital Advisors's Thermo Fisher Scientific position peaked at $78K in Q4 2024.
2,454 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2025.

Based on Runnymede Capital Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.